trending Market Intelligence /marketintelligence/en/news-insights/trending/s41oesvqu7y0yoxaydt4gg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

PDL BioPharma no longer pursuing Neos Therapeutics

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


PDL BioPharma no longer pursuing Neos Therapeutics

PDL BioPharma Inc. said it is no longer looking to acquire Neos Therapeutics Inc.

The Incline Village, Nev.-based biotech company had offered to buy Texas-based Neos for $10.25 per share in cash, but its offer had been rejected by the target company's board.

"While we believe we have provided a compelling opportunity for Neos' shareholders, we were unable to agree on terms that were in the best interest of our shareholders. We continue to pursue other opportunities and be disciplined in the process," PDL CEO John McLaughlin said in a statement.